Clinical Trial Update: An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study [Phase 3]

View source ↗

Summary

Phase 3 open-label extension studies (ADVANCE-2 and ACCORD-2) evaluating long-term safety of AXS-05 in Alzheimer's-related agitation have been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Status: TERMINATED